according to GLOBACAN 2020, BC is the fifth leading cancer, with an estimated 1 in 6 cancer deaths, in a majority of countries. However, the exact cause that leads to BC progression still needs to be determined. Here,
At least 50 non-overlapping tumor cells were evaluated for each tissue microarray core. EGFR copy number was classified into six categories, as described previously30, 31: disomy (≤2 copies in >90% of cells); low trisomy (≤2 copies in ≥40% of cells, three copies in 10–40% of cell...
[Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1]. 目的:探讨非小细胞肺癌表皮生长因子受体(EGFR)基因突变,间变性淋巴瘤激酶(ALK)及ROS1基因融合突变情况与临床病理特征的关系,并分析驱动基因共突变的病例.方法:收集福建医科大学附属协和医院...
In supporting this notion, we found that Rankl expression in the hypertrophic chondrocytes next to the marrow cavity correlates well with the number of osteoclasts at the junction, implying that chondrocytes at both POC and SOC use a cell non-autonomous mechanism to regulate cartilage resorption by...
HDAC1 is the prototypical human histone deacetylase (HDAC) enzyme responsible for catalyzing the removal of acetyl group from lysine residues on many substrate proteins. By deacetylating histones and non-histone proteins, HDAC1 has a profound effect on t
EGFR inhibition is an effective treatment in the minority of non-small cell lung cancer (NSCLC) cases harboring EGFR-activating mutations, but not in EGFR wild-type (EGFRwt) tumors. Here we demonstrate that EGFR inhibition triggers an antiviral defense pathway in NSCLC. Inhibiting mutant EGFR tr...
Clin Chem Lab Med 2013;51:2325-9.Olsen DA, Jakobsen EH, Brandslund I. Quantification of EGFR autoantibodies in the amplification phe- nomenon of HER2 in breast cancer. Clin Chem Lab Med. 2013 Dec 1; 51(12):2325-9. doi: 10.1515/ cclm-2013-0166 PMID: 24021599...
The discovery of sensitizing epidermal growth factor receptor (EGFR) mutations as a predictive marker of sensitivity to first-generation EGFR tyrosine kinase inhibitors (TKIs) has dramatically changed the paradigm of care for advanced non-small cell lung cancer (NSCLC) patients. Unfortunately, the majo...
microtubule depolymerization and mitosis in tumor cells K Rea1, M Sensi2, A Anichini2, S Canevari*,1 and A Tomassetti*,1 FAK is a non-receptor tyrosine kinase contributing to migration and proliferation downstream of integrin and/or growth factor receptor signaling of normal and malignant cells...
Among non-small-cell lung cancer (NSCLC) patients that are non-smokers, 15-50% have EGFR mutations and 15-25% have K-Ras mutations, both of which play an important role in tumor progression and metastasis [67, 68]. Therefore, many researchers are developing cancer treatments targeting EGFR...